Last reviewed · How we verify
ME-401
At a glance
| Generic name | ME-401 |
|---|---|
| Also known as | PWT-143 |
| Sponsor | Kyowa Kirin Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (PHASE1)
- Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL) (PHASE2)
- ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma (PHASE1, PHASE2)
- Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) (PHASE2)
- Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) (PHASE3)
- Zandelisib + Tazemetostat in R/R Follicular Lymphoma (PHASE1, PHASE2)
- A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma (PHASE1)
- Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ME-401 CI brief — competitive landscape report
- ME-401 updates RSS · CI watch RSS
- Kyowa Kirin Co., Ltd. portfolio CI